This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol evaluates the use of 6 months of suppressive oral acyclovir therapy in neonates following herpes simplex virus disease involving the central nervous system. This is a double-blind, randomized study. Following 21 days of IV acyclovir, neonates will be randomized to receive suppressive acyclovir therapy or to receive identically flavored placebo for a period of six months. Cutaneous HSV recurrences in either group will be treated with open label oral acyclovir.
Showing the most recent 10 out of 570 publications